U.S. License Holder:
Date of License:
SOLIRIS (eculizumab) is a complement inhibitor indicated for:
The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis;
The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy;
The treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)
Novartis Pharma AG; Novartis Vaccines and Diagnostics Inc.
Alexion Pharmaceuticals, Inc.; Biogen IDEC, Inc.; MedImmune LLC